AMENDED AND RESTATED

EMPLOYMENTAGREEMENT

ThisAMENDEDANDRESTATEDEMPLOYMENTAGREEMENT(this“Agreement”) is made and entered into as of April 14, 2026, by and between Kailera Therapeutics, Inc., a Delaware corporation (the “Company”), and Jamie Coleman (the “Executive”), and will be effective as of the Effective Date (as defined below). Certain capitalized terms used, but not otherwise defined, in this Agreement are defined in Section 6 hereof.

WHEREAS,theCompanyandExecutivepreviouslyenteredintothatcertainEmployment Agreement, dated as of January 3, 2025 (the “Prior Agreement”);

WHEREAS,effectiveonthedateuponwhichtheRegistrationStatementonFormS-1filed with the Securities and Exchange Commission relating to the registered underwritten public offeringoftheCompany’scommonstockbecomeseffective(the“EffectiveDate”),theCompany desires to continue to benefit from the services of the Executive, and the Executive desires to continue to render such services, on the terms and conditions set forth in this Agreement; and

WHEREAS, effective as of the Effective Date, this Agreement will supersede the Prior Agreement in all respects.

NOW, THEREFORE, in consideration of the mutual covenants contained herein and intending to be legally bound hereby, the Company and the Executive agree as follows, effective on the Effective Date:

1.

Employment,PositionandDuties.

(a)

TheExecutivewillcontinuetobeemployedbytheCompany,onafull-time basis,astheChiefCommercialOfficeroftheCompany,reportingtotheCompany’sChief Executive Officer (the “CEO”).

(b)

…

AMENDED AND RESTATED EMPLOYMENTAGREEMENT

ThisAMENDEDANDRESTATEDEMPLOYMENTAGREEMENT(this“Agreement”) is made and entered into as of April 14, 2026, by and between Kailera Therapeutics, Inc., a Delawarecorporation(the“Company”),andPaulBurgess(the“Executive”),andwillbeeffective as of the Effective Date (as defined below). Certain capitalized terms used, but not otherwise defined, in this Agreement are defined in Section 6 hereof.

WHEREAS,theCompanyandExecutivepreviouslyenteredintothatcertainEmployment Agreement, dated as of September 14, 2024 (the “Prior Agreement”);

WHEREAS,effectiveonthedateuponwhichtheRegistrationStatementonFormS-1filed with the Securities and Exchange Commission relating to the registered underwritten public offeringoftheCompany’scommonstockbecomeseffective(the“EffectiveDate”),theCompany desires to continue to benefit from the services of the Executive, and the Executive desires to continue to render such services, on the terms and conditions set forth in this Agreement; and

WHEREAS, effective as of the Effective Date, this Agreement will supersede the Prior Agreement in all respects.

NOW, THEREFORE, in consideration of the mutual covenants contained herein and intending to be legally bound hereby, the Company and the Executive agree as follows, effective on the Effective Date:

1.

Employment,PositionandDuties.

(a)

TheExecutivewillcontinuetobeemployedbytheCompany,onafull-time basis,astheChiefOperatingOfficerandChiefBusinessOfficeroftheCompany,reporting to the Company’s Chief Executive Officer (the “CEO”).

(b)

…

SECONDAMENDEDANDRESTATED

EMPLOYMENT AGREEMENT

ThisSECONDAMENDEDANDRESTATEDEMPLOYMENTAGREEMENT(this “Agreement”)ismadeandenteredintoasofApril15,2026,byandbetweenKaileraTherapeutics, Inc.,aDelawarecorporation(the“Company”),andRonaldRenaud(the“Executive”),andwillbe effective as of the Effective Date (as defined below). Certain capitalized terms used, but not otherwise defined, in this Agreement are defined in Section 6 hereof.

WHEREAS, the Company and Executive previously entered into that certain Amended and Restated Employment Agreement, dated as of December 6, 2024 (the “Prior Agreement”);

WHEREAS,effectiveonthedateuponwhichtheRegistrationStatementonFormS-1filed with the Securities and Exchange Commission relating to the registered underwritten public offeringoftheCompany’scommonstockbecomeseffective(the“EffectiveDate”),theCompany desires to continue to benefit from the services of the Executive, and the Executive desires to continue to render such services, on the terms and conditions set forth in this Agreement; and

WHEREAS, effective as of the Effective Date, this Agreement will supersede the Prior Agreement in all respects.

NOW, THEREFORE, in consideration of the mutual covenants contained herein and intending to be legally bound hereby, the Company and the Executive agree as follows, effective on the Effective Date:

1.

Employment,PositionandDuties.

(a)

TheExecutivewillcontinuetobeemployedbytheCompany,onafull-time basis, as the President and Chief Executive Officer of the Company, reporting to the Company’s Board of Directors (the “Board”).

(b)

…

July 4, 2026

Michael Vyvoda

Re:    Employment Terms

Dear Michael:

Enovix Corporation (the “Company”) is pleased to offer you the position of Chief Operating Officer reporting to the Chief Executive Officer (the “CEO”) subject to the terms and conditions provided herein effective as of the date you commence employment hereunder, which is expected to be on or around July 29, 2026 (the “Start Date”). Your base salary will be $440,000 (the “Base Salary”) which will be subject to adjustment pursuant to the Company’s employee compensation policies as may be in effect from time to time and periodic reviews, less payroll deductions and withholdings. You will be eligible for an annual discretionary bonus and your annual bonus target will be 60% of your Base Salary. The bonus payout will be based on achievement of specific performance goals and will be subject to the terms and conditions of the Enovix Bonus Plan specification, your continued employment through the payment date and approval by the Board of Directors (the “Board”).

…

INDEMNITY AGREEMENT

This Indemnity Agreement (the “Agreement”), dated as of _____________, 2026 is made by and between First Tracks Biotherapeutics, Inc., a Delaware corporation (the “Company”), and [Insert Name], a director, officer or key employee of the Company or one of the Company’s Subsidiaries or Affiliates (as those terms are defined below) or other service provider who satisfies the definition of Indemnifiable Person set forth below (“Indemnitee”).

RECITALS

A. The Company is aware that competent and experienced persons are increasingly reluctant to serve as representatives of corporations unless they are protected by comprehensive liability insurance and indemnification, due to increased exposure to litigation costs and risks resulting from their service to such corporations, and due to the fact that the exposure frequently bears no relationship to the compensation of such representatives;

…

SUBLEASE AGREEMENT

This Sublease Agreement (“Sublease”) is dated as of June 15, 2026 (the “Effective Date”), by and between ANAPTYSBIO, INC., a Delaware corporation (“Sublandlord”), and FIRST TRACKS BIOTHERAPEUTICS, INC., a Delaware corporation, (“Subtenant”).

RECITALS

A.Sublandlord currently leases certain premises from WATERIDGE PROPERTY OWNER, LP, a Delaware limited partnership (the “Master Landlord”), pursuant to the terms and conditions of that certain Lease dated May 4, 2020, as amended by that certain First Amendment to Lease Agreement, dated April 5, 2021 (as so amended, the “Master Lease”). Pursuant to the Master Lease, Sublandlord currently leases from Master Landlord approximately 45,057 rentable square feet of space (the “Premises”) located in that certain building located in 10770 Wateridge Circle, San Diego, CA 92121 (the “Building”), as more specifically described in the Lease. Sublandlord represents that a true, correct and complete copy of the Master Lease is attached hereto as Exhibit A. All terms capitalized but undefined herein shall have the meanings ascribed to them in the Master Lease.

B.The Term of the Master Lease is scheduled to expire by its terms on August 31, 2031 (“Lease Expiration Date”).

CB.Sublandlord desires to sublease the Premises to Subtenant and Subtenant desires to sublease the Premises from Sublandlord pursuant to the terms and conditions of this Sublease.

AGREEMENT

Now, Therefore, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, Sublandlord and Subtenant hereby agree as follows:

…

Exhibit 10.3 1 AMENDMENT NO. 3 TO AMENDED AND RESTATED CREDIT AGREEMENT AMENDMENT NO. 3 TO AMENDED AND RESTATED CREDIT AGREEMENT dated as of August 6, 2026 (this "Agreement") among NCPCIF SPV III, LLC as Borrower A (the "Borrower A"), NCPCIF BSL SPV I, LLC, as Borrower B (the "Borrower B" and, together with Borrower A, each a "Borrower" and together, the "Borrowers"), Nuveen Churchill Private Capital Income Fund, as Servicer (the "Servicer"), the Lenders party hereto, The Bank of Nova Scotia, as Administrative Agent (the "Administrative Agent"), U.S. Bank Trust Company, National Association, as Collateral Agent (the "Collateral Agent") and collateral administrator (the "Collateral Administrator") and U.S. Bank National Association, as Custodian (the "Custodian"). The Borrowers, the Servicer, the Lenders party thereto, the Administrative Agent, the Collateral Agent, the Collateral Administrator and the Custodian are parties to an Amended and Restated Credit Agreement dated as of May 22, 2025 (as amended by Amendment No. 1 to Amended and Restated Credit Agreement, dated as of November 7, 2025, Amendment No. 2 to Amended and Restated Credit Agreement, dated as of April 13, 2026 and as may be further amended, modified and supplemented and in effect from time to time, the "Credit Agreement", and the Credit Agreement as amended by this Agreement, the "Amended Credit Agreement"). Pursuant to the terms of Section 12.5 of the Credit Agreement, the Borrowers, the Servicer, the Administrative Agent and the Lenders (representing all Lenders party to the Credit Agreement) party hereto

…

Exhibit 10.2 AMERICASACTIVE:23007305.4 LOAN SALE AND CONTRIBUTION AGREEMENT by and between NUVEEN CHURCHILL PRIVATE CAPITAL INCOME FUND, as the Seller and NCPCIF SPV VI, LLC, as the Buyer Dated as of August 6, 2026

---

TABLE OF CONTENTS Page -i- AMERICASACTIVE:23007305.4 ARTICLE I DEFINITIONS..........................................................................................................1 Section 1.01 Definitions. ...........................................................................................1 Section 1.02 Other Terms. .........................................................................................4 Section 1.03 Computation of Time Periods...............................................................4 Section 1.04 Interpretation.........................................................................................4 Section 1.05 References.............................................................................................5 Section 1.06 Calculations. .........................................................................................5 ARTICLE II TRANSFER OF LOAN ASSETS...........................................................................5 Section 2.01 Sale, Transfer, Assignment and Contribution.......................................5 Section 2.02 Purchase Price.......................................................................................7 Section 2.03 Payment of Purchase Price. ..................................................................7 Section 2.04 Release of

…

Exhibit 10.1 CREDIT AGREEMENT dated as of August 6, 2026 among NCPCIF SPV VI, LLC, as the Borrower, NUVEEN CHURCHILL PRIVATE CAPITAL INCOME FUND, as Servicer, the Lenders Referred to Herein, U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Loan Agent, THE BANK OF NOVA SCOTIA, as Syndication Agent, and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Collateral Agent and Collateral Administrator and U.S. BANK NATIONAL ASSOCIATION, Custodian i TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INTERPRETATION ................................................................2 Section 1.1 Definitions.................................................................................................2 Section 1.2 Accounting Terms and Determinations, UCC Terms and S&P Rating ......................................................................................................67 Section 1.3 Assumptions and Calculations with respect to Collateral Loans ............68 Section 1.4 Cross-References; References to Agreements ........................................71 Section 1.5 Reference to Secured Parties ..................................................................71 ARTICLE II THE LOANS ............................................................................................................71 Section 2.1 The Commitments ...................................................................................71 Section 2.2 Making of the Loans ...............................................................................72 Section 2.3 Evidence of Indebtedness; Notes

…

-1- AMENDMENT NO. 2 TO THE LIMITED LIABILITY COMPANY AGREEMENT OF AT UMBRELLA LLC July 22, 2026 This Amendment No. 2 (the “Amendment”) to the Limited Liability Company Agreement of AT Umbrella LLC, a Delaware limited liability company (the “Company”), dated as of December 16, 2025 and as amended (the “Agreement”), is entered into by the undersigned Members of the Company effective as of the date first written above (the “Effective Date”). All capitalized terms used but not defined herein have the respective meanings ascribed to such terms in the Agreement. RECITALS WHEREAS, pursuant to Section 13.09(a) of the Agreement, the Agreement may be amended with the written consent of Members constituting a majority in interest of all Members, which majority must include Aggregator (the “Requisite Majority”); and WHEREAS, the undersigned Members, constituting the Requisite Majority, desire to amend the Agreement as provided herein. NOW, THEREFORE, BE IT RESOLVED, that the Agreement is hereby amended as follows: 1. Amendment to Section 1.01(a). The defined term “Permitted Exchange” in Section 1.01(a) of the Agreement is hereby amended and restated in its entirety to read as follows (with additions to the prior version of Section 1.01(a) indicated in blue text and deletions indicated in struckthrough red text): “Permitted Exchange” means an Exchange of Class X Umbrella Units or LTIP Units by an a Redeeming Member or LTIP Exchanging Member, respectively, except as otherwise prohibited or restricted by (i) this Agreement, (ii) any underwriter lock-up agreement applicable to such

…

EMPLOYMENT AGREEMENT

This Employment Agreement (the “Agreement”) is entered into as of August 12, 2026 (the “Effective Date”), by and between Centuri Group, Inc. (“Employer”), a Nevada corporation, whose parent company is Centuri Holdings, Inc., a Delaware corporation (the “Company”), and Kelly Youngblood (“Executive”). For purposes of this Agreement, the “Company Group” shall mean, collectively, the Company and its subsidiaries (including Employer).

I.    RECITALS

WHEREAS, Employer has offered employment to Executive, and Executive has agreed to accept such employment, in each case, subject to the terms and conditions of this Agreement

NOW, THEREFORE, in consideration of the promises and obligations of Employer and Executive under this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Employer and Executive hereby agree as follows:

II.    TERMS OF EMPLOYMENT

A.    Position and Duties. Employer hereby employs Executive as Executive Vice President, Chief Financial Officer of the Company. Executive shall devote his full business time, attention and effort to the performance of his duties pursuant to this Agreement. Executive shall be an executive officer of the Company, duly appointed as such by the Board of Directors of the Company (the “Board”), and Executive shall report directly to the Company’s President and Chief Executive Officer (the “CEO”).

…

​

Exhibit 10.4

PURCHASE AGREEMENT

THIS PURCHASE AGREEMENT (this “Agreement”), dated as of August 11, 2026, is made by and between ARC Group International Ltd. (the “Investor”), and Lulu’s Fashion Lounge Holdings, Inc., a Delaware corporation (the “Company”).

WHEREAS, the parties desire that, upon the terms and subject to the conditions contained herein, the Company shall have the right to issue and sell to the Investor, from time to time as provided herein, and the Investor shall purchase from the Company, up to Four Million Five Hundred Thousand Dollars ($4,500,000) of the Company’s common stock, par value US$0.001 per share (the “Common Stock”); and

WHEREAS, the shares of Common Stock are listed for trading on the Principal Market under the symbol “LVLU”; and

WHEREAS, the offer and sale of the Shares (as defined below) issuable hereunder to the Investor will be made in reliance upon Section 4(a)(2) under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (the “Securities Act”), or upon such other exemption from the registration requirements of the Securities Act as may be available with respect to any or all of the sales of shares of Common Stock to be made to the Investor hereunder.

NOW, THEREFORE, the parties hereto agree as follows:

ARTICLE I

CERTAIN DEFINITIONS

“Advance” shall mean the portion of the Commitment Amount requested by the Company in an Advance Notice.

…